Tempest Therapeutics Inc (TPST  ) released new and updated results from the planned data analysis of an ongoing Phase 1b/2 study of TPST-1120 in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).

TPST-1120 shows clinical superiority in multiple study endpoints when combined with atezolizumab and bevacizumab (triplet arm) in a randomized comparison to atezolizumab and bevacizumab.

The confirmed objective response rate (cORR or confirmed ORR) was 30% for the TPST-1120 triplet arm versus 13.3% for the atezolizumab + bevacizumab control arm.

The duration of response (DoR) has not yet been reached.

The progression-free survival (PFS) was a median of 7 months for the TPST-1120 arm versus 4.27 months for the control arm; HR of 0.7 favors the TPST-1120 arm and is not yet mature.

Median overall survival not reached for the TPST-1120 arm (10.84 months, NE) versus 15.1 months (7.49 months, NE) for the control arm; HR 0.59 favors the TPST-1120 arm and is not yet mature.

40% of the patients in the TPST-1120 arm were on treatment (16/40) compared to 16.7% in the atezolizumab + bevacizumab control arm (5/30).

TPST-1120 remains well tolerated, with safety data comparable between the two arms.

Price Actions: TPST shares are up 800.40% at $2.16 during the premarket session on the last check Wednesday.